BCG predicts rising temperatures will increase default risk in 30% of agri and housing loans by 2030, highlighting climate ...

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

A new BCG survey highlights significant dissatisfaction among women with consumer goods, financial services, and healthcare ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

Leading Global Asset Manager B Capital Opens Regional Headquarters in Doha to Help Advance the VC and Startup Ecosystem in the RegionNEW YORK--(BUSINESS WIRE)--B Capital today announced that it has ...

In a tight economy, disciplined cost management is often a better path than absorbing margin pressures or passing costs to ...

The platform can be harnessed for TB, potentially improving protection and durability of immunity in a way that traditional ...

ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an "alternative source ...

In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated they were unable to treat patients in the last 12 months due to a lack of access to TICE® BCG. The alternative BCG source has ...

The authorization was granted to ImmunityBio, the manufacturer of Anktiva ® (nogapendekin alfa inbakicept-pmln), an interleukin-15 receptor agonist, indicated with BCG for adult patients with BCG ...